Company Filing History:
Years Active: 2011
Title: The Innovative Contributions of Yannève Rolland in Biomedical Research
Introduction
Yannève Rolland is a prominent inventor based in Montreal, Canada, known for his significant contributions to biomedical research. With his innovative work focused on the regulation of plasminogen activation and cell migration, Rolland has made a notable impact on therapies for treating cancer and thrombo-embolic diseases.
Latest Patents
Yannève Rolland holds a patent for his invention titled "Compound and method for regulating plasminogen activation and cell migration." This invention introduces novel regulators of plasminogen activation and their application in regulating cell migration, plasminolysis, angiogenesis, and fibrinolysis. The patent outlines methods for treating serious medical conditions such as cancer and heart stroke, specifically through a process involving melanotransferrin (p97) and other components that effectively regulate plasminogen activation.
Career Highlights
Yannève Rolland has built a career that integrates cutting-edge research with practical application in medicine. His role at Transfert Plus allows him to collaborate with a team of experts to further develop and refine his inventions. Throughout his career, Rolland has been dedicated to finding innovative solutions to complex health challenges.
Collaborations
In his professional journey, Yannève Rolland has collaborated with notable coworkers, Richard Béliveau and Michel Demeule. Together, they work towards advancing their collective research goals, combining expertise and resources to push the boundaries of biomedical innovation.
Conclusion
Yannève Rolland's contributions to the field of biomedical research have not only resulted in impactful patents but also demonstrate the importance of innovation in developing treatments for critical health issues. His continued work at Transfert Plus, along with valuable collaborations, underscores the drive for advancements that enhance medical science and improve patient outcomes.